Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsHongxia Wang, Haibo Qiu, Ning Li, Xueqing Zhao
Life of this patent
Estimating the term…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsHongxia Wang, Haibo Qiu, Ning Li, Xueqing Zhao
Estimating the term…
The present invention provides methods to quickly and efficiently assess the effect of antibody variants, including PTMs, e.g., glycosylation, oxidation, and deamidation variants, on the binding between the antibody and FcRn. In particular, the present invention is based, at least in part, on the development of an online, two dimension liquid chromatography (2D-LC) method for assessing binding between antibody variants and FcRn. In one aspect, the online 2D-LC is coupled with mass spectrometry (MS). The present invention allows for differentiation of antibody variants by peak pattern and retention time profile by affinity chromatography, and identification of these variants by mass spectrometry analysis.
A method for assessing binding affinity of an antibody variant to the neonatal Fc receptor (FcRn), or a fragment thereof, using an online two dimension liquid chromatography system, the method comprising:
A method for assessing binding of an antibody variant to the neonatal Fc receptor (FcRn), or a fragment thereof, using an online two dimension liquid chromatography system, the method comprising:
Dependencies are inferred from the claim text.